Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000796459 | SCV000935973 | likely benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001336099 | SCV001529396 | uncertain significance | Hypokalemic periodic paralysis, type 1 | 2018-10-24 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Fulgent Genetics, |
RCV005004429 | SCV002814078 | uncertain significance | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5; Thyrotoxic periodic paralysis, susceptibility to, 1; Congenital myopathy 18 | 2024-06-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003166141 | SCV003865512 | uncertain significance | Inborn genetic diseases | 2023-02-15 | criteria provided, single submitter | clinical testing | The c.2963G>A (p.R988H) alteration is located in exon 24 (coding exon 24) of the CACNA1S gene. This alteration results from a G to A substitution at nucleotide position 2963, causing the arginine (R) at amino acid position 988 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |